Literature DB >> 18005069

Sigma 1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y.

Alfred Meurs1, Ralph Clinckers, Guy Ebinger, Yvette Michotte, Ilse Smolders.   

Abstract

The potent anticonvulsant properties of neuropeptide Y (NPY) are generally attributed to a Y2 receptor-mediated inhibition of glutamatergic synaptic transmission. Independent studies have shown that NPY increases brain dopamine content, possibly via interaction with sigma 1 receptors. Recently, we showed that increased extracellular hippocampal dopamine attenuates pilocarpine-induced limbic seizures via activation of hippocampal D2 receptors. Our aim in this study was to elucidate the role of increased hippocampal dopamine in the mechanism of the anticonvulsant action of NPY and to investigate the involvement of Y2 and sigma 1 receptors in this process. Limbic seizures were evoked in freely moving rats by intrahippocampal administration of pilocarpine via a microdialysis probe. NPY was administered intracerebroventricularly, intrahippocampally via the microdialysis probe, or coadministered intrahippocampally with the D2 receptor antagonist remoxipride, the Y2 receptor antagonist BIIE0246 or the sigma 1 receptor antagonist BD1047. Changes in hippocampal extracellular dopamine were monitored, and behavioural changes indicative of seizure activity were scored. Intracerebroventricular (10 nmol/3 microL) and intrahippocampal (20-50 microm) NPY administration increased hippocampal dopamine and attenuated pilocarpine-induced seizures. Hippocampal D2 receptor blockade (4 microm remoxipride) reversed the anticonvulsant effect of NPY. Y2 receptor blockade (1 microm BIIE0246) reversed the anticonvulsant effect of NPY but did not prevent NPY-induced increases in hippocampal dopamine. Sigma 1 receptor blockade (10 microm BD1047) abolished NPY-induced increases in hippocampal dopamine and reversed the anticonvulsant effect of NPY. Our results indicate that NPY-induced increases in hippocampal dopamine are mediated via sigma 1 receptors and contribute to the anticonvulsant effect of NPY via increased activation of hippocampal D2 receptors. This novel mechanism of anticonvulsant action of NPY is separate from, and may be complementary to, the well established Y2 receptor-mediated inhibition of hippocampal excitability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005069     DOI: 10.1111/j.1460-9568.2007.05911.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  10 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

2.  Neuropeptide Y signaling in the central nucleus of amygdala regulates alcohol-drinking and anxiety-like behaviors of alcohol-preferring rats.

Authors:  Huaibo Zhang; Amul J Sakharkar; Guangbin Shi; Rajesh Ugale; Anand Prakash; Subhash C Pandey
Journal:  Alcohol Clin Exp Res       Date:  2009-12-18       Impact factor: 3.455

3.  Allosteric modulation of sigma-1 receptors elicits anti-seizure activities.

Authors:  Lin Guo; Yanke Chen; Rui Zhao; Guanghui Wang; Eitan Friedman; Ao Zhang; Xuechu Zhen
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

4.  Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats.

Authors:  Teruo Hayashi; Zuzana Justinova; Eri Hayashi; Gianfrancesco Cormaci; Tomohisa Mori; Shang-Yi Tsai; Chanel Barnes; Steven R Goldberg; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

Review 5.  Sigma Receptors and Substance Use Disorders.

Authors:  Valentina Sabino; Callum Hicks; Pietro Cottone
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 3.650

6.  Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.

Authors:  Jo Sourbron; Ilse Smolders; Peter de Witte; Lieven Lagae
Journal:  Front Pharmacol       Date:  2017-04-06       Impact factor: 5.810

Review 7.  The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson's Disease (PD) and Major Depressive Disorder (MDD).

Authors:  Kai Yang; Changcai Wang; Taolei Sun
Journal:  Front Pharmacol       Date:  2019-05-21       Impact factor: 5.810

8.  Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.

Authors:  Daniel Ryskamp; Lili Wu; Jun Wu; Dabin Kim; Gerhard Rammes; Michal Geva; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2018-12-27       Impact factor: 5.996

Review 9.  Neuropeptides as targets for the development of anticonvulsant drugs.

Authors:  Elke Clynen; Ann Swijsen; Marjolein Raijmakers; Govert Hoogland; Jean-Michel Rigo
Journal:  Mol Neurobiol       Date:  2014-04-06       Impact factor: 5.590

Review 10.  Pharmacological effects of berberine on mood disorders.

Authors:  Jie Fan; Kun Zhang; Yang Jin; Bingjini Li; Shuohui Gao; Jiaming Zhu; Ranji Cui
Journal:  J Cell Mol Med       Date:  2018-11-18       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.